Jazz Pharmaceuticals is set to acquire Chimerix, a biotechnology company developing oncology therapies and others for a deal size of approximately $935m set to close in Q2 2025. The acquisition adds ...

McAdams-DeMarco has received speaking fees from Chiesi. Segev has served as a consultant for and/or received speaking fees from pharmaceutical and healthcare companies AstraZeneca, Behring ...

UK-based specialist Amryt Pharma is looking to expand in 2018 after acquiring two rare disease treatments. A relative newcomer to the niche rare disease market, Amryt Pharma was founded by former ...

Yet in the past few years, B Corp has garnered controversy over awarding its logo to corporations such as Nestlé-owned Nespresso, the pharmaceutical Chiesi Group which is part of an industry ...

Amryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®) DUBLIN, Ireland, and Boston MA, March 31, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global ...

Collaborators are listed at the end of the paper.

Located on the outskirts of the historic Italian city – home to Verdi and myriad architectural gems – the press launch and tour of the €85 million Chiesi development was a quintessentially ...

Chiesi Farmaceutici, Renovion, and Others. The major markets for Chimeric Antigen Receptor (CAR) T-Cell Therapy include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan.

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan ...

Amryt comprises a strong and growing portfolio of commercial and development assets. Amryt’s commercial business comprises two orphan disease products – metreleptin (Myalept®/ Myalepta®) and ...